NCT07590934 Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
| NCT ID | NCT07590934 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | AstraZeneca |
| Condition | Metastatic Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 152 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2029-09-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 152 participants in total. It began in 2026-06-03 with a primary completion date of 2029-09-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Eligibility Criteria
Inclusion Criteria: 1. Participants with a diagnosis of histologically confirmed adenocarcinoma of the prostate (no small cell, neuroendocrine, sarcomatoid, spindle or signet cell). 2. Minimum life expectancy of 3 months or more. 3. Eastern Cooperative Oncology Group (ECOG) performance status of O or 1 at screening, with no deterioration. 4. PCWG3 (Prostate Cancer Working Group 3) modified RECIST Version 1.1 evaluable disease. 5. Must have received at least one novel androgen receptor pathway inhibitor (ARPI), such as enzalutamide or darolutamide or apalutamide or abiraterone acetate. 6. Must have one or more unresectable metastatic lesions. 7. Must have had prior orchiectomy and/or ongoing androgen deprivation therapy, and a castrate level of serum testosterone (\<50ng/dL or \<l.7nmol/L). 8. Progressive metastatic castration-resistant prostate cancer (mCRPC) following the most recent treatment at time of study entry. 9. Adequate organ and marrow function. 10. Non sterilised participants who are sexually active with a partner of childbearing potential must use a condom (plus spermicide, if available), must refrain from fathering a child, freezing or donating sperm, and it is recommended for the partner to also use a highly effective contraceptive method. Inclusion Criteria for Sub study 1: 1. Must have received a single line of ARPI, such as enzalutamide, darolutamide, apalutamide or abiraterone acetate. 2. PSMA positive mCRPC by computed tomography positron emission tomography, obtained with PSMA ligand defined as at least 1 PSMA positive metastatic lesion with tracer uptake greater than liver, and no PSMA negative lesions. All measurable or intraprostatic lesions must be PSMA positive. 3. Capable of self-administering oral formulations. Exclusion Criteria: 1. Any evidence of non adenocarcinomatous forms of prostate cancer (including small cell, spindle cell, signet cell, neuroendocrine, sarcomatous). 2. Known, unresolved urinary tract obstruction. 3. Participants with a history of central nervous system metastases. 4. Symptomatic malignant spinal cord compression or findings indicative of impending cord compression. 5. Participants with a history of leptomeningeal carcinomatosis. 6. Previous or concurrent cancer distinct from the cancer under investigation in primary site or histology . 7. Concurrent serious medical conditions. 8. Previous history of interstitial lung disease or non-infectious pneumonitis. 9. Participants with a history or clinical/laboratory features suggestive of myelodysplastic syndrome or acute myeloid leukaemia. 10. Persistent toxicities caused by previous therapy. 11. Participants unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with absorption. 12. Active infection, including tuberculosis, hepatitis C virus, and hepatitis B virus infection. 13. Known hypersensitivity to study intervention or any of their excipients. Exclusion Criteria for Sub study 1: 1. History of uncontrolled seizures or requirement for \>2 antiepileptic drugs. 2. History of severe brain injury or stroke. 3. Skeletal metastases demonstrating a superscan appearance on bone scan. 4. Participants have received prior therapy with AZD9574 or more than 1 prior line of any other Poly-ADP-ribose polymerase inhibitor (PARPi)-based regimen (either as a treatment or as maintenance).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07590934 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 99 Years, studying Metastatic Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07590934 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07590934 currently recruiting?
Yes, NCT07590934 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07590934 trial being conducted?
This trial is being conducted at Encino, United States, South Pasadena, United States, Miami, United States, Tampa, United States and 11 additional locations.
Who is sponsoring the NCT07590934 clinical trial?
NCT07590934 is sponsored by AstraZeneca. The trial plans to enroll 152 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.